This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) has revealed plans to double the number of drugs in registrational trials over the next 18 months.
Bristol Myers Squibb (BMS) has shared six-year follow-up results from a late-stage study of Opdivo (nivolumab) plus Yervoy (ipilimumab) in certain lung cancer patients.
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Camzyos (mavacamten) for use across NHS England and Wales in adults with symptomatic
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and ... However, the
The plan already faces at least seven court challenges from leading drugmakers and industry groups, including Merck &Co, Bristol Myers Squibb, Johnson &Johnson, Boehringer Ingelheim and the Pharmaceutical Research and Manufacturers
Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has been approved by the European Commission (EC) as an adjuvant treatment in adults and adolescents with completely resected stage 2B or 2C melanoma.
More from news
Approximately 221 fully matching, plus 953 partially matching documents found.
That trio tracked slightly ahead of the companies providing the leading digital CX, where Bristol Myers Squibb (66), Boehringer Ingelheim (65) and Merck (also 65) made up its top three.
But pharma is moving, and at pace. Europe’s recent Clinical Trials Regulations enshrine the need for diversity in clinical trials while GSK and Bristol-Myers Squibb are among companies laying
Catherine Owen(pictured) is Senior Vice President of Major Markets at Bristol Myers Squibb.
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point.
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
More from intelligence
Approximately 4 fully matching, plus 51 partially matching documents found.
Anthony Mancini joins from Bristol-Myers Squibb. Biotech company Genmab has appointed Anthony Mancini (pictured above) as executive vice president and to the newly created position of chief operating officer. ... Most recently, he led Bristol-Myers
Gilead appoints Michael Quigley to lead research team. A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.
Bristol-Myers Squibb.
The latest movers in pharma. Bristol-Myers Squibb. Bristol-Myers Squibb has announced changes to its leadership team, following the retirement of its current executive vice president of corporate affairs and
Roger Tomlins (pictured right), who joins Wilmington from Bristol-Myers Squibb, has worked in healthcare for over 16 years, in both the pharmaceutical industry and the NHS.
More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.
Then there was Michael Bradley, Associate Director, Corporate Affairs at Bristol Myers Squibb, who also expounded upon the rise in reputation of pharma companies during and immediately after the pandemic, the
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space. HCPs use a wide variety of digital channels to connect with the medical community. According to
future. The session titled A Strategic Approach to Revolutionizing Digital Impact for Medical Affairs, presented by Luca Dezzani (Johnson &Johnson), Bora Erdemli (ZS Associates), Stacey Gorski (AstraZeneca), and Shaji Kalathil (Bristol ... Myers Squibb),
The Excellence in Healthcare Partnerships category for our work with Bristol Myers Squibb.Our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome,
In the Excellence in Healthcare Partnerships category, working with Bristol Myers Squibb, our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome, the
More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.
No results were found
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...